TCM
CRL icon

Tekla Capital Management’s Charles River Laboratories CRL Stock Holding History

Tekla Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$23.4M Sell
111,183
-6,900
-6% -$1.37M 0.91% 33
2023
Q1 		$23.8M Buy
118,083
+45,408
+62% +$10.3M 0.91% 31
2022
Q4 		$15.8M Hold
72,675
– – 0.6% 41
2022
Q3 		$14.3M Buy
72,675
+24,781
+52% +$5.35M 0.59% 42
2022
Q2 		$10.2M Sell
47,894
-14,096
-23% -$3.44M 0.4% 59
2022
Q1 		$17.6M Hold
61,990
– – 0.62% 44
2021
Q4 		$23.4M Sell
61,990
-16,494
-21% -$6.41M 0.75% 36
2021
Q3 		$32.4M Buy
78,484
+23,810
+44% +$9.89M 1.04% 30
2021
Q2 		$20.2M Buy
54,674
+11,600
+27% +$3.87M 0.66% 41
2021
Q1 		$12.5M Buy
43,074
+14,920
+53% +$4.15M 0.43% 61
2020
Q4 		$7.04M Sell
28,154
-2,600
-8% -$619K 0.25% 102
2020
Q3 		$6.96M Buy
30,754
+12,287
+67% +$2.55M 0.26% 87
2020
Q2 		$3.22M Hold
18,467
– – 0.12% 134
2020
Q1 		$2.33M Sell
18,467
-2,500
-12% -$375K 0.11% 127
2019
Q4 		$3.2M Sell
20,967
-4,100
-16% -$568K 0.12% 135
2019
Q3 		$3.32M Buy
25,067
+10,900
+77% +$1.46M 0.14% 109
2019
Q2 		$2.01M Buy
14,167
+3,527
+33% +$478K 0.08% 133
2019
Q1 		$1.54M Sell
10,640
-12,030
-53% -$1.58M 0.06% 140
2018
Q4 		$2.57M Hold
22,670
– – 0.11% 116
2018
Q3 		$3.05M Hold
22,670
– – 0.11% 122
2018
Q2 		$2.54M Hold
22,670
– – 0.1% 127
2018
Q1 		$2.42M Sell
22,670
-63,134
-74% -$6.81M 0.09% 127
2017
Q4 		$9.39M Sell
85,804
-41,296
-32% -$4.49M 0.36% 56
2017
Q3 		$13.7M Hold
127,100
– – 0.49% 40
2017
Q2 		$12.9M Hold
127,100
– – 0.48% 49
2017
Q1 		$11.4M Sell
127,100
-500
-0.4% -$42.5K 0.44% 50
2016
Q4 		$9.72M Buy
127,600
+12,600
+11% +$957K 0.41% 58
2016
Q3 		$9.58M Buy
+115,000
New +$9.64M 0.37% 63

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Tekla Capital Management's CRL Position: Q2 2023 in Review

Tekla Capital Management reduced its Charles River Laboratories (CRL) stake by 5.8% in Q2 2023, selling an estimated $1.37M and leaving 111,183 shares worth $23.4M. The position accounts for 0.91% of the portfolio, ranked #33.

Tekla Capital Management first reported a position in CRL in Q3 2016 and has held it in 28 quarters since. The position peaked at $32.4M in Q3 2021. 613 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • Tekla Capital Management held 111,183 shares of Charles River Laboratories worth $23.4M as of Q2 2023.
  • Tekla Capital Management sold 6,900 Charles River Laboratories shares in Q2 2023, an estimated $1.37M.
  • Charles River Laboratories made up 0.91% of Tekla Capital Management's portfolio in Q2 2023, its #33 holding.
  • Tekla Capital Management first reported a position in Charles River Laboratories in Q3 2016 and has held it in 28 quarters since.
  • Tekla Capital Management's Charles River Laboratories position peaked at $32.4M in Q3 2021.
  • 613 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.